Melanoma & Skin Cancer

Prior treatment with PD-1 or MAPK inhibitors resulted in lower objective response rates with adoptive cell transfer of autologous tumor-infiltrating lymphocytes in patients with metastatic melanoma vs patients who were naïve to these agents.

The FDA and the European Medicines Agency have accepted applications seeking the approval of tebentafusp for use in the treatment of adult patients with HLA-A*02:01–positive metastatic uveal melanoma.

Distinct subgroups of pediatric melanocytic lesions, which were identified by an integrated clinicopathologic and genomic analysis, were found to have different clinical behaviors, suggesting that this combined diagnostic modality could inform individualized diagnoses and treatments for patients with these rare malignancies.

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.

The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.

Drs Richard D. Carvajal and Marlana M. Orloff highlight variables that should be considered when assessing the appropriateness for treating patients with uveal melanoma with tebentafusp.

Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.

What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.

Potential sequencing strategies with novel therapies such as tebentafusp for uveal melanoma.

The FDA has granted a fast track designation to nemvaleukin alfa as a potential therapeutic option for patients with mucosal melanoma.

Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.

Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.

Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.

A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.

The FDA has granted an orphan drug designation to alrizomadlin as a potential therapeutic option for patients with stage IIB-IV melanoma.

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.

The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

The European Commission has granted approval to cemiplimab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer whose tumor cells have at least 50% PD-L1 expression and no EGFR, ALK, or ROS1 aberrations and are ineligible for definitive chemoradiation.

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

James A. DeCaprio, MD, discusses the incidence of Merkel cell carcinoma, risk factors for the disease, established treatment options, and investigational regimens on the horizon.

Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.